A PhaseI/II study of nine patients with hemophilia B who underwent Spark Therapeutics’ SPK-9001 gene therapy are promising, despite two adverse autoimmune reactions.
A new study shows that individuals treated with intravenous immune globulin (IVIG) for Guillain-Barré syndrome are at increased risk of developing hypoalbuminemia (reduced albumin levels).
The Centers for Medicare andMedicaid Services has released the Use of New or Increased Pass Through Payments in Medicaid Managed Care final rule.
A new study shows that brains of people genetically inclined toward Alzheimer’s are likely to show abnormal immune reactions as early as seven years before the expected onset of the disease.
The U.S. Food and Drug Administration has approved Bio Products Laboratory’s Gammaplex 10% (immune globulin intravenous [human] 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura in adults.
The Advisory Committee on Immunization Practices has changed its recommendation for the human papilloma virus from three doses to two doses of the vaccine prior to age 15.
A recent study shows that people can be infected with the Ebola virus and not show any symptoms.
Congress passed the 21st Century Cures Act, which reforms the current standards and appropriations for biomedical research and provides five years of funding for the National Institutes of Health and the U.S. Food and Drug Administration.
The U.S. Department of Health and Human Services, along with 15 other agencies, finalized a rule whose provisions safeguard individuals who participate in research, most of which will go into effect in 2018.
Researchers have found that sunlight’s rays speed up helper and killer T cells in the skin.
A new vaccine that blocks the pain-numbing effects of the drugs oxycodone and hydrocodone has shown success in animal models.
Researchers in Melbourne have developed an effective, rapid and economical treatment for Ebola using antibodies from horses.
